High-value molecules going off-patent – from an emerging markets perspective

Emerging markets are much more heterogeneous place compared to regulated markets like the US and EU. Regulatory norms, application of intellectual property rights, disease pattern, and market size vary considerably between developing countries.

All this means that market access strategy, portfolio management strategy would be quite different for these markets.

In emerging and for emerging markets

The truth is that there is no way to compare emerging markets with markets like the US. In many emerging markets, pharmaceutical manufacturing is dominated by mid and small-cap companies. These companies primarily specialize in producing off-patent branded generics. Some of these countries have quite a robust local pharmaceutical market like India, Brazil, or Russia.

In emerging markets, even the scope of intellectual property rights varies. For example, 46 least developed countries simply qualify for drug patents waiver. Some of these countries, like Bangladesh, have a healthy pharma market and local production.

To complicate things further, many countries like India or Russia may provide drug patent waivers for certain life-saving drugs on humanitarian grounds. Just take the example of Remdesivir. In 2020, the Russian supreme court backed a local manufacturer granting it the right to produce the patented drug.

Read the source article at PharmaSources
2021-08-30 04:00:00